-
Company Profile
![]()
H. Lundbeck AS – Company Profile
H. Lundbeck AS (Lundbeck), a subsidiary of The Lundbeck Foundation, carries out the research, development, manufacturing, and marketing of pharmaceuticals for the treatment of central nervous system (CNS) diseases including psychiatric and neurological disorders. The company's products are indicated for the treatment of Alzheimer's disease, migraine, depression, Parkinson's disease, schizophrenia, alcohol dependence, anxiety, bipolar I disorder, depression, anxiety, psychosis, and epilepsy, among others. It operates production facilities in Denmark, Italy, and France, and research centers in the US and Denmark....
Add to Basket -
Product Insights
NewAllergic Rhino-Conjunctivitis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Allergic Rhino-Conjunctivitis Clinical Trials Market Report Overview The Allergic Rhino-Conjunctivitis clinical trial market research report provides an overview of the Allergic Rhino-Conjunctivitis clinical trials scenario. This report provides top-line data relating to the clinical trials on Allergic Rhino-Conjunctivitis and includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type....
-
Product Insights
NewSocial Anxiety Disorder (SAD/Social Phobia) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Social Anxiety Disorder (SAD/Social Phobia) Clinical Trials Market Report Overview The social anxiety disorder (SAD/social phobia) trial market research report provides an overview of the social anxiety disorder (SAD/social phobia) trials scenario. The report provides top-line data relating to the clinical trials on social anxiety disorder. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LuAF-87908 in Alzheimer’s Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. LuAF-87908 in Alzheimer's Disease Drug Details: LuAF-87908 is under development for the treatment of Alzheimer’s...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Sucunamostat in Proteinuria
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Sucunamostat in ProteinuriaDrug Details:Sucunamostat (SCO-792) is under development for the treatment of obesity subjects with type...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LuAG-13909 in Congenital Adrenal Hyperplasia (Adrenogenital Syndrome)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.LuAG-13909 in Congenital Adrenal Hyperplasia (Adrenogenital Syndrome)Drug Details:LuAG-13909 is under development for the treatment of congenital...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LuAG-09222 in Grass Pollen Allergy
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.LuAG-09222 in Grass Pollen Allergy Drug Details:LuAG-09222 is under development for the treatment of grass pollen...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LuAG-09222 in Migraine
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.LuAG-09222 in MigraineDrug Details:LuAG-09222 is under development for the treatment of grass pollen allergic rhiniti, chronic and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Exlinkibart in Castration-Resistant Prostate Cancer (CRPC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Exlinkibart in Castration-Resistant Prostate Cancer (CRPC)Drug Details:Exlinkibart (LVGN-6051) is under development for the treatment of advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lu-AG22515 in Systemic Lupus Erythematosus
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Lu-AG22515 in Systemic Lupus Erythematosus Drug Details: Lu-AG22515 is under development for the treatment of neuromyelitis...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MAX-4 in Gastric Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.MAX-4 in Gastric Cancer Drug Details:MAX-4 is under development for the treatment of myelodysplastic syndrome, acute...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lu-AG22515 in Rheumatoid Arthritis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Lu-AG22515 in Rheumatoid Arthritis Drug Details: Lu-AG22515 is under development for the treatment of neuromyelitis optica...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lu-AG22515 in Multiple Sclerosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Lu-AG22515 in Multiple Sclerosis Drug Details: Lu-AG22515 is under development for the treatment of neuromyelitis optica...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lu-AG22515 in Neuromyelitis Optica (Devic’s Syndrome)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Lu-AG22515 in Neuromyelitis Optica (Devic’s Syndrome) Drug Details: Lu-AG22515 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Obicetrapib in Atherosclerosis
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Obicetrapib in Atherosclerosis Drug Details: Obicetrapib (AMG-899, DEZ-001, TA-8995) is under development for Alzheimer’s...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Camsirubicin in Soft Tissue Sarcoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Camsirubicin in Soft Tissue Sarcoma Drug Details:camsirubicin is under development for the treatment of advanced soft...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Inetagugene Geperpavec in Harlequin Ichthyosis (Autosomal Recessive Congenital Ichthyosis 4B)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Inetagugene Geperpavec in Harlequin Ichthyosis (Autosomal Recessive Congenital Ichthyosis 4B)Drug Details:KB-105 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Elcubragistat in Post-Traumatic Stress Disorder (PTSD)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Elcubragistat in Post-Traumatic Stress Disorder (PTSD)Drug Details: Elcubragistat (ABX-1431) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ivonescimab in Peritoneal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ivonescimab in Peritoneal Cancer Drug Details: Ivonescimab (AK-112) is under development for the treatment of...
-
Product Insights
New![]()
Innovation in pharma: neuroprotective drugs
Why settle for outdated information when you can stay ahead of the curve with our comprehensive report? Our team of industry experts has meticulously researched and analyzed the latest trends, innovations, and emerging technologies in the pharma industry’s neuroprotective drugs innovations. By leveraging our report, you'll gain invaluable insights that can revolutionize your business strategies and give you a competitive edge. Why Choose Our Report? Unparalleled Expertise: Our research team consists of seasoned analysts with deep knowledge and experience in...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.